NCT03128047View on ClinicalTrials.gov

HUMC 1612: Optune NovoTTF-200A System

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

April 6, 2017

Primary Completion Date

July 8, 2024

Study Completion Date

April 5, 2025

Conditions
High Grade GliomaEpendymoma
Interventions
DEVICE

Optune NovoTTF-200A System

Optune NovoTTF-200A System receive treatment with 200kHz for a minimum of 18 hours per day in 28 day cycles combined with Temozolomide and Bevacizumab.

Trial Locations (2)

32806

Arnold Palmer Hospital for Children, Orlando

07601

Joseph M. Sanzari Children's Hospital at Hackensack University Medical Center, Hackensack

All Listed Sponsors
collaborator

NovoCure Ltd.

INDUSTRY

lead

Hackensack Meridian Health

OTHER

NCT03128047 - HUMC 1612: Optune NovoTTF-200A System | Biotech Hunter | Biotech Hunter